301 related articles for article (PubMed ID: 25780300)
21. Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase?
Pascale A; Serfaty L
J Hepatol; 2013 Feb; 58(2):391-4. PubMed ID: 23063419
[TBL] [Abstract][Full Text] [Related]
22. Sustained virological response to pegylated interferon plus ribavirin leads to normalization of liver stiffness in hepatitis C virus-infected patients.
Macías J; Rivero A; Cifuentes C; Camacho A; Neukam K; Rivero-Juárez A; Mira JA; Torre-Cisneros J; Gómez-Mateos J; Pineda JA
Enferm Infecc Microbiol Clin; 2013; 31(7):424-9. PubMed ID: 23453582
[TBL] [Abstract][Full Text] [Related]
23. Outcome of antiviral treatment in patients with chronic genotype 1 HCV hepatitis. A retrospective study in 507 patients.
Sporea I; Sirli R; Curescu M; Gheorghe L; Popescu A; Bota S; Iacob S
J Gastrointestin Liver Dis; 2010 Sep; 19(3):261-4. PubMed ID: 20922189
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of boceprevir co-administration versus pegylated interferon-α2b and ribavirin only for patients with hepatitis C genotype 1 in Singapore.
Dan YY; Ferrante SA; Elbasha EH; Hsu TY
Antivir Ther; 2015; 20(2):209-16. PubMed ID: 25105844
[TBL] [Abstract][Full Text] [Related]
25. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis.
Mira JA; Rivero-Juárez A; López-Cortés LF; Girón-González JA; Téllez F; de los Santos-Gil I; Macías J; Merino D; Márquez M; Ríos-Villegas MJ; Gea I; Merchante N; Rivero A; Torres-Cornejo A; Pineda JA;
Clin Infect Dis; 2013 Jun; 56(11):1646-53. PubMed ID: 23429381
[TBL] [Abstract][Full Text] [Related]
26. Boceprevir and telaprevir-based triple therapy for chronic hepatitis C: virological efficacy and impact on kidney function and model for end-stage liver disease score.
Virlogeux V; Pradat P; Bailly F; Funingana G; Gonçalves F; Maynard M; Hartig-Lavie K; Amiri M; Zoulim F
J Viral Hepat; 2014; 21(9):e98-e107. PubMed ID: 24612466
[TBL] [Abstract][Full Text] [Related]
27. How to optimize HCV therapy in genotype 1 patients with cirrhosis.
Bourlière M; Wendt A; Fontaine H; Hézode C; Pol S; Bronowicki JP
Liver Int; 2013 Feb; 33 Suppl 1():46-55. PubMed ID: 23286846
[TBL] [Abstract][Full Text] [Related]
28. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
Angelico M; Koehler-Horst B; Piccolo P; Angelico F; Gentile S; Francioso S; Tarquini P; Vecchia RD; Ponti L; Pilleri G; Barlattani A; Grieco A; Soccorsi F; Guarascio P; Demelia L; Sorbello O; Rossi Z; Forlini G; Zaru S; Bandiera F;
Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072
[TBL] [Abstract][Full Text] [Related]
29. Health-related quality of life and severity of fatigue in HIV/HCV co-infected patients before, during, and after antiviral therapy with pegylated interferon plus ribavirin.
Mandorfer M; Payer BA; Scheiner B; Breitenecker F; Aichelburg MC; Grabmeier-Pfistershammer K; Rieger A; Trauner M; Peck-Radosavljevic M; Reiberger T
Liver Int; 2014 Jan; 34(1):69-77. PubMed ID: 23890125
[TBL] [Abstract][Full Text] [Related]
30. Rapid Prediction of Treatment Futility of Boceprevir with Peginterferon-Ribavirin for Taiwanese Treatment Experienced Hepatitis C Virus Genotype 1-Infected Patients.
Yang CC; Tsai WL; Su WW; Huang CF; Cheng PN; Lo CC; Tseng KC; Mo LR; Wang CH; Hsu SJ; Lai HC; Su CW; Liu CJ; Peng CY; Yu ML
PLoS One; 2015; 10(9):e0137852. PubMed ID: 26368130
[TBL] [Abstract][Full Text] [Related]
31. A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients.
Braun DL; Rauch A; Aouri M; Durisch N; Eberhard N; Anagnostopoulos A; Ledergerber B; Müllhaupt B; Metzner KJ; Decosterd L; Böni J; Weber R; Fehr J;
PLoS One; 2015; 10(7):e0133028. PubMed ID: 26176696
[TBL] [Abstract][Full Text] [Related]
32. [Efficacy and safety of boceprevir based triple therapy in Hungarian patients with hepatitis C genotype 1 infection, advanced stage fibrosis and prior treatment failure].
Hunyady B; Abonyi M; Csefkó K; Gervain J; Haragh A; Horváth G; Jancsik V; Makkai E; Müller Z; Ribiczey P; Sipos B; Szabó O; Szalay F; Szentgyörgyi L; Tornai I; Újhelyi E; Varga M; Weisz G; Makara M
Orv Hetil; 2016 Aug; 157(34):1366-74. PubMed ID: 27546804
[TBL] [Abstract][Full Text] [Related]
33. Direct-acting antiviral-based triple therapy on alpha-fetoprotein level in chronic hepatitis C patients.
Takayama K; Furusyo N; Ogawa E; Ikezaki H; Shimizu M; Murata M; Hayashi J
World J Gastroenterol; 2015 Apr; 21(15):4696-706. PubMed ID: 25914481
[TBL] [Abstract][Full Text] [Related]
34. Lower liver stiffness in patients with sustained virological response 4 years after treatment for chronic hepatitis C.
Andersen ES; Moessner BK; Christensen PB; Kjær M; Krarup H; Lillevang S; Weis N
Eur J Gastroenterol Hepatol; 2011 Jan; 23(1):41-4. PubMed ID: 21079513
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.
Hézode C; Fontaine H; Dorival C; Zoulim F; Larrey D; Canva V; De Ledinghen V; Poynard T; Samuel D; Bourliere M; Alric L; Raabe JJ; Zarski JP; Marcellin P; Riachi G; Bernard PH; Loustaud-Ratti V; Chazouilleres O; Abergel A; Guyader D; Metivier S; Tran A; Di Martino V; Causse X; Dao T; Lucidarme D; Portal I; Cacoub P; Gournay J; Grando-Lemaire V; Hillon P; Attali P; Fontanges T; Rosa I; Petrov-Sanchez V; Barthe Y; Pawlotsky JM; Pol S; Carrat F; Bronowicki JP;
Gastroenterology; 2014 Jul; 147(1):132-142.e4. PubMed ID: 24704719
[TBL] [Abstract][Full Text] [Related]
36. High sustained virological response rate to combination therapy in genotype 1 patients with histologically mild hepatitis C.
Gheorghe L; Iacob S; Grigorescu M; Sporea I; Sirli R; Damian D; Gheorghe C; Iacob R
J Gastrointestin Liver Dis; 2009 Mar; 18(1):51-6. PubMed ID: 19337634
[TBL] [Abstract][Full Text] [Related]
37. IP-10 correlates with hepatitis C viral load, hepatic inflammation and fibrosis and predicts hepatitis C virus relapse or non-response in HIV-HCV coinfection.
Reiberger T; Aberle JH; Kundi M; Kohrgruber N; Rieger A; Gangl A; Holzmann H; Peck-Radosavljevic M
Antivir Ther; 2008; 13(8):969-76. PubMed ID: 19195322
[TBL] [Abstract][Full Text] [Related]
38. Triple therapy with boceprevir or telaprevir in a European cohort of cirrhotic HIV/HCV genotype 1-coinfected patients.
Miailhes P; Gilbert C; Lacombe K; Arends JE; Puoti M; Rockstroh JK; Sogni P; Fontaine H; Rosenthal E; Winnock M; Loko MA; Wittkop L; Dabis F; Salmon D;
Liver Int; 2015 Sep; 35(9):2090-9. PubMed ID: 25650873
[TBL] [Abstract][Full Text] [Related]
39. Female patients in fertile age with chronic hepatitis C, easy genotype, and persistently normal transaminases have a 100% chance to reach a sustained virological response.
Floreani A; Cazzagon N; Boemo DG; Baldovin T; Baldo V; Egoue J; Antoniazzi S; Minola E
Eur J Gastroenterol Hepatol; 2011 Nov; 23(11):997-1003. PubMed ID: 21915057
[TBL] [Abstract][Full Text] [Related]
40. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
Napoli N; Giannelli G; Parisi CV; Antonaci A; Maddalena G; Antonaci S
New Microbiol; 2005 Jan; 28(1):13-21. PubMed ID: 15782622
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]